A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models

[Image: see text] Here we describe a new approach for tumor targeting in which augmented concentrations of Fe(II) in cancer cells and/or the tumor microenvironment triggers drug release from an Fe(II)-reactive prodrug conjugate. The 1,2,4-trioxolane scaffold developed to enable this approach can in...

Descripción completa

Detalles Bibliográficos
Autores principales: Spangler, Benjamin, Fontaine, Shaun D., Shi, Yihui, Sambucetti, Lidia, Mattis, Aras N., Hann, Byron, Wells, James A., Renslo, Adam R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5184369/
https://www.ncbi.nlm.nih.gov/pubmed/27936709
http://dx.doi.org/10.1021/acs.jmedchem.6b01470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5184369/
https://www.ncbi.nlm.nih.gov/pubmed/27936709
http://dx.doi.org/10.1021/acs.jmedchem.6b01470

Ejemplares similares